{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:11:20Z","timestamp":1767921080886,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-025-03816-6","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T06:15:25Z","timestamp":1739168125000},"page":"9267-9278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function: exposure simulation and individualized dosing adjustments"],"prefix":"10.1007","volume":"398","author":[{"given":"Rongrong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinglin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"9","key":"3816_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","volume":"57","author":"I Bilbao-Meseguer","year":"2018","unstructured":"Bilbao-Meseguer I, Rodr\u00edguez-Gasc\u00f3n A, Barrasa H et al (2018) Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet 57(9):1107\u20131121","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3816_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/0091270003256065","volume":"43","author":"TD Bjornsson","year":"2013","unstructured":"Bjornsson TD, Wagner JA, Donahue SR et al (2013) A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 43(9):943\u2013967","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3816_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/ern.10.3","volume":"10","author":"AZ Crepeau","year":"2010","unstructured":"Crepeau AZ, Treiman DM (2010) Levetiracetam: a comprehensive review. Expert Rev Neurother 10(2):159\u2013171","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"3816_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.xphs.2023.12.025","volume":"113","author":"Y Duan","year":"2024","unstructured":"Duan Y, Yang X, Zhang M et al (2024) Adaptive dosage strategy of levetiracetam in Chinese epileptic patients: focus on pregnant women. J Pharm Sci 113(5):1385\u20131394","journal-title":"J Pharm Sci"},{"issue":"10","key":"3816_CR5","doi-asserted-by":"publisher","first-page":"e3969","DOI":"10.1002\/bmc.3969","volume":"31","author":"L Engelbrecht","year":"2017","unstructured":"Engelbrecht L, Grobler CJ et al (2017) A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma\/serum of patients with epilepsy. Biomed Chromatogr Bmc 31(10):e3969","journal-title":"Biomed Chromatogr Bmc"},{"issue":"Suppl 4","key":"3816_CR6","first-page":"40","volume":"42","author":"J French","year":"2008","unstructured":"French J (2008) Use of levetiracetam in special populations. Epilepsia 42(Suppl 4):40\u201343","journal-title":"Epilepsia"},{"issue":"5","key":"3816_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.0013-9580.2004.06204.x","volume":"45","author":"JA French","year":"2004","unstructured":"French JA, Kanner AM, Bautista J et al (2004) Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45(5):401\u2013409","journal-title":"Epilepsia"},{"issue":"3","key":"3816_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1681\/ASN.2004070549","volume":"16","author":"M Froissart","year":"2005","unstructured":"Froissart M, Rossert J, Jacquot C et al (2005) Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16(3):763\u2013773","journal-title":"J Am Soc Nephrol"},{"key":"3816_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eplepsyres.2018.09.015","volume":"148","author":"MI Gulcebi","year":"2018","unstructured":"Gulcebi MI, Kendirli T, Turgan ZA et al (2018) The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy. Epilepsy Res 148:17\u201322","journal-title":"Epilepsy Res"},{"issue":"6","key":"3816_CR10","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.xphs.2020.02.018","volume":"109","author":"MP Hern\u00e1ndez-Mitre","year":"2020","unstructured":"Hern\u00e1ndez-Mitre MP, Medell\u00edn-Garibay SE, Rodr\u00edguez-Leyva I et al (2020) Population pharmacokinetics and dosing recommendations of levetiracetam in adult and elderly patients with epilepsy. J Pharm Sci 109(6):2070\u20132078","journal-title":"J Pharm Sci"},{"issue":"3","key":"3816_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/FTD.0000000000000291","volume":"38","author":"S Ito","year":"2016","unstructured":"Ito S, Yano I, Hashi S et al (2016) Population pharmacokinetic modeling of levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data. Ther Drug Monit 38(3):371\u2013378","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3816_CR12","doi-asserted-by":"publisher","first-page":"149S","DOI":"10.18433\/jpps30081","volume":"21","author":"D Jarvie","year":"2018","unstructured":"Jarvie D, Mahmoud SH (2018) Therapeutic drug monitoring of levetiracetam in select populations. J Pharm Pharm Sci 21(1):149S-176S","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"3816_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ et al (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25(3):347\u2013363","journal-title":"Ther Drug Monit"},{"issue":"12","key":"3816_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/js9702168","volume":"86","author":"JA Johnson","year":"1997","unstructured":"Johnson JA (1997) Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 86(12):1328\u20131333","journal-title":"J Pharm Sci"},{"issue":"5","key":"3816_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5414\/CP203058","volume":"56","author":"YS Jung","year":"2018","unstructured":"Jung YS, Lee SM, Park MS et al (2018) Population pharmacokinetic model of levetiracetam in Korean neonates with seizures. Int J Clin Pharmacol Ther 56(5):217\u2013223","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"3816_CR16","first-page":"1611","volume":"42","author":"EH Kossoff","year":"2010","unstructured":"Kossoff EH, Bergey GK, Freeman JM et al (2010) Levetiracetam psychosis in children with epilepsy. Epilepsia J Int League Against Epilepsy 42(12):1611\u20131613","journal-title":"Epilepsia J Int League Against Epilepsy"},{"issue":"11","key":"3816_CR17","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1016\/j.xphs.2016.08.012","volume":"105","author":"XG Li","year":"2016","unstructured":"Li XG, Wu YX, Sun SS et al (2016) Population pharmacokinetics of vancomycin in postoperative neurosurgical patients and the application in dosing recommendation. J Pharm Sci 105(11):3425\u20133431","journal-title":"J Pharm Sci"},{"issue":"1","key":"3816_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13318-017-0422-1","volume":"43","author":"X Li","year":"2017","unstructured":"Li X, Sun S, Wang Q et al (2017a) Population pharmacokinetics of combined intravenous and local intrathecal administration of meropenem in aneurysm patients with suspected intracranial infections after craniotomy. Eur J Drug Metab Pharmacokinet 43(1):45\u201353","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"3816_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clinthera.2017.11.005","volume":"40","author":"X Li","year":"2017","unstructured":"Li X, Wu Y, Sun S et al (2017b) Factors influencing norvancomycin concentration in plasma and cerebrospinal fluid in patients after craniotomy and dosing guideline: a population approach. Clin Ther 40(1):74\u201382","journal-title":"Clin Ther"},{"issue":"3","key":"3816_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-020-00963-2","volume":"60","author":"ZR Li","year":"2021","unstructured":"Li ZR, Wang CY, Zhu X et al (2021) Population pharmacokinetics of levetiracetam: a systematic review. Clin Pharmacokinet 60(3):305\u2013318","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3816_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/bcp.15572","volume":"89","author":"Y Li","year":"2023","unstructured":"Li Y, Wang ML, Guo Y et al (2023a) Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy. Br J Clin Pharmacol 89(3):1152\u20131161","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3816_CR22","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00210-023-02798-7","volume":"397","author":"Z Li","year":"2023","unstructured":"Li Z, Yang SY, Hua ZX et al (2023b) Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Naunyn-Schmiedebergs Arch Pharmacol 397(5):3351\u20133362","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"3816_CR23","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1038\/s41401-022-00892-9","volume":"43","author":"XQ Liu","year":"2022","unstructured":"Liu XQ, Zhang YF, Ding HY et al (2022) Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. Acta Pharmacol Sin 43(10):2723\u20132734","journal-title":"Acta Pharmacol Sin"},{"key":"3816_CR24","doi-asserted-by":"publisher","first-page":"723731","DOI":"10.3389\/fphar.2021.723731","volume":"12","author":"Y Luo","year":"2021","unstructured":"Luo Y, Luo Y, Luo Y et al (2021) Augmented renal clearance: what have we known and what will we do? Front Pharmacol 12:723731","journal-title":"Front Pharmacol"},{"issue":"2","key":"3816_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.pnpbp.2007.10.015","volume":"32","author":"M Mazza","year":"2008","unstructured":"Mazza M, Martini A, Scoppetta M et al (2008) Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 32(2):539\u2013543","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"3816_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3109\/00207454.2013.866951","volume":"124","author":"GK Mbizvo","year":"2013","unstructured":"Mbizvo GK, Dixon P, Hutton JL et al (2013) The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int J Neurosci 124(9):627\u2013634","journal-title":"Int J Neurosci"},{"issue":"2","key":"3816_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","volume":"27","author":"JM Nicolas","year":"1999","unstructured":"Nicolas JM, Collart P, Gerin B et al (1999) In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 27(2):250\u2013254","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3816_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"PN Patsalos","year":"2000","unstructured":"Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85(2):77\u201385","journal-title":"Pharmacol Ther"},{"issue":"11","key":"3816_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43(11):707\u2013724","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3816_CR30","first-page":"1239","volume":"49","author":"PN Patsalos","year":"2010","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD et al (2010) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Comm Ther Strateg Epilepsia 49(7):1239\u20131276","journal-title":"ILAE Comm Ther Strateg Epilepsia"},{"issue":"6","key":"3816_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","volume":"46","author":"E Pigeolet","year":"2007","unstructured":"Pigeolet E, Jacqmin P, Sargentini-Maier ML et al (2007) Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 46(6):503\u2013512","journal-title":"Clin Pharmacokinet"},{"key":"3816_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2017.02.011","volume":"132","author":"SJ Rhee","year":"2017","unstructured":"Rhee SJ, Shin JW, Lee S et al (2017) Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res 132:8\u201314","journal-title":"Epilepsy Res"},{"issue":"4","key":"3816_CR33","first-page":"426","volume":"72","author":"SD Shorvon","year":"2002","unstructured":"Shorvon SD, van Rijckevorsel K (2002) A new antiepileptic drug. J Neurol Neurosurg Psychiatry 72(4):426\u2013429","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2\u20133","key":"3816_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.eplepsyres.2007.07.011","volume":"76","author":"E Snoecka","year":"2007","unstructured":"Snoecka E, Jacqmin P, Sargentini-Maier ML et al (2007) Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res 76(2\u20133):140\u2013147","journal-title":"Epilepsy Res"},{"issue":"6","key":"3816_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/aps.2012.57","volume":"33","author":"YH Wang","year":"2012","unstructured":"Wang YH, Wang L, Lu W et al (2012) Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin 33(6):845\u2013851","journal-title":"Acta Pharmacol Sin"},{"key":"3816_CR36","doi-asserted-by":"crossref","unstructured":"Yang S, Wei J, Pan X et al (2024) Development and validation of individualized tacrolimus dosing software for Chinese pediatric liver transplantation patients: a population pharmacokinetic approach. Eur J Clin Pharmacol 80(9):1409\u20131420","DOI":"10.1007\/s00228-024-03717-2"},{"issue":"3","key":"3816_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4103\/0253-7613.132195","volume":"46","author":"SA Zaki","year":"2014","unstructured":"Zaki SA et al (2014) Levetiracetam-induced acute psychosis in a child. Indian J Pharmacol 46(3):341\u2013342","journal-title":"Indian J Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03816-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:54:25Z","timestamp":1757134465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3816"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03816-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was carried out with the official endorsement of the institutional ethics committee of Chinese PLA General Hospital (S2021-535\u201301) and informed written consents were obtained from all participants prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}